Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease
CLEVELAND, July 28 /PRNewswire/ -- More than 340,000(2) women suffer from postmenopausal osteoporosis (PMO) in Ohio and more than 900,000(3) are at risk for the disease. According to a census report on the prevalence of osteoporosis, the number of women suffering from the...
PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patie...
Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder
ROCHESTER, Minn., Feb. 11 /PRNewswire-USNewswire/ -- In a study published in The American Journal of Psychiatry , a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., attempted to identify what factors make some people with bipolar depression more likely to experience treatment-...
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) today announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for th...
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
(Nasdaq: OREX ) today announced changes to conserve the Company's resources,
focus its efforts on its late-stage obesity programs and realign its
The key aspects of these changes are as follows:
Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on
innovative oncology therapies, announced today that it will be exploring
strategic alternatives for its preclinical research programs in order to a...
Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution
BOSTON, Oct. 15 /PRNewswire-FirstCall/ -- Perceptive Informatics, one
of the industry's leading eClinical technology providers and a subsidiary
of PAREXEL International Corporation (Nasdaq: PRXL ), announced today that
it has enhanced its TrialWorks(R) solution, a specialized Clinical Trial
Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
FORT WORTH, Texas, Sept. 30 /PRNewswire-FirstCall/ -- Wound Care
Innovations, LLC, a subsidiary of Wound Management
Technologies, Inc., (OTC
Bulletin Board: WNDM), announced today that it will attend and exhibit at
the Wound Care Seminar: Clinical and Economical Realities in Boston. This
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
MONTREAL, Sept. 22 /PRNewswire/ -- Enobia Pharma, a biotech company
focused on developing novel therapeutics for serious bone disorders, today
announced key appointments to add commercial and manufacturing expertise to
the Company's senior management
team in conjunction with the recent
Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc.
(NYSE: ALO ), a global specialty pharmaceutical company, today announced
results from its Phase III pivotal efficacy trial that showed ALO-01
(EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO ), a
global healthcare company, presented data from a phase 3 clinical study
(LEAD(TM) 4) today at the 44th annual meeting of the European Association
for the Study of Diabetes that demonstrated adding the investigational new
Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
Company Focuses Operations, Updates Zingo Launch Progress and Adlea Registration Strategy Conference Call Today at 11:30 am ET
SOUTH SAN FRANCISCO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Anesiva,
Inc. (Nasdaq: ANSV ) announced today that the compa...
Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders
CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- As biotechnology,
pharmaceutical and medical device companies increasingly move clinical
trials beyond their own borders to other parts of the world, such as Asia,
Eastern Europe and South America, complicated regulatory environments
challenge those f...
Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
ASHBURN, Va., Aug. 8 /PRNewswire/ -- Innocoll, Inc., a privately-held
biopharmaceutical company, announced that the last patient has been dosed
in the first of three ongoing phase 2 clinical trials sponsored by its
wholly owned subsidiary, Innocoll Technologies Ltd, to investigate
Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
FORT WORTH, Texas, July 30 /PRNewswire/ -- Wound Care Innovations, LLC,
a subsidiary of Wound Management
Technologies, Inc., (OTC Bulletin Board:
WNDM), announced today an evidence based study with a NE podiatric clinic
evaluating the clinical performance of their advanced wound care collagen
New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
BETHLEHEM, Pa., June 23 /PRNewswire/ -- A new blood test may make it
easier for oncologists to accurately measure and personalize 5-fluorouracil
(5-FU) dosing for patients undergoing continuous infusion chemotherapy
regimens. Data from a multicenter trial showed that a nanoparticle-based
Saladax Biomedical's 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
BETHLEHEM, Pa., June 17 /PRNewswire/ -- Saladax Biomedical, a company
specializing in chemotherapy therapeutic drug monitoring, today announced
CE mark registration in the European Union (EU) for its 5-FU Personalized
(PCM(R)) assay on the Olympus AU400 Clinical
Wound Management Technologies, Inc. Announces Evidence Based Study
FORT WORTH, Texas, June 3 /PRNewswire-FirstCall/ -- Wound Care
Innovations, LLC, a subsidiary of Wound Management
(formerly MB Software Corporation (OTC Bulletin Board: MBSB)) announced
today that it will begin an evidence based study evaluating the clinical
performance of t...
University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
New data presented at annual American Transplant Congress in Toronto
MIAMI, June 2 /PRNewswire/ -- Manuel R. Carreno, MD, and colleagues in
the Departments of Surgery and Pathology at the University of Miami -
Lawrence Miller School of Medicine have corroborated the value of
Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
BETHLEHEM, Pa., May 2 /PRNewswire/ -- Can a blood test improve
treatment outcomes for colorectal cancer patients? Recently published
studies indicate that personalized chemotherapy dose management
measuring drug levels in patients' blood and adjusting them for optimal
dosing -- can substant...
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
ASHBURN, Va., Jan. 4 /PRNewswire/ -- Innocoll, Inc., a privately-held
specialty pharmaceutical company, announced that the first of a series of
planned phase 2 clinical trials sponsored by its wholly owned subsidiary,
Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL
Micromet Announces Changes in Management Team
BETHESDA, Md., Dec. 14 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ) ("Micromet" or the "Company"), a biopharmaceutical company
developing novel, proprietary antibodies for the treatment of cancer,
inflammation and autoimmune diseases, today announced the resignation of
Lilly Receives NCQA Design Certification for Depression Care Management Program
INDIANAPOLIS, Nov. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company
(NYSE: LLY ) has received Program Design Certification from the National
Committee for Quality Assurance (NCQA) for its Tools that Empower(TM)
Depression Care Management
Program. Tools that Empower(TM) Depression Care Manag...
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Interim Results From Open-Label Follow-up Include Longer-term Safety Findings
BOSTON, Oct. 26 /PRNewswire/ -- Adults with Attention Deficit
Hyperactivity Disorder (ADHD) treated with CONCERTA(R) OROS(R)
methylphenidate HCl Extended-release Tablets showed signif...
Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
BOULDER, Colo., Oct. 22 /PRNewswire/ -- Sciona, Inc., a leader in the
science of nutrigenetics, today announced the results of a pivotal study
published by Nutrition Journal, which demonstrates substantial advances in
long term weight management
and blood glucose levels as a result of
Cellectar Expands Clinical Management Team
- Appoints Director, Clinical Operations and Manager, Medical Affairs -
MADISON, Wis., Oct. 3 /PRNewswire/ -- Cellectar LLC, (Cellectar), a
privately-held radiopharmaceuticals company that designs and develops
products to detect, treat and monitor human cancers, today announced the
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
NKTR-118 Currently in Phase 1 Clinical Development for the Treatment of Opioid Bowel Dysfunction
SAN CARLOS, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Nektar
Therapeutics (Nasdaq: NKTR ) presented positive results this week from Phase
1 and preclinical studies of NKTR-...
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a
privately held biopharmaceutical company developing novel cancer therapies,
today announced that it has hired industry veterans Eric D. Malek as vice
president of corporate development and Deborah A. Thomas as vice president
New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
TRILIPIX has now been studied in combination with the most commonly used doses of rosuvastatin calcium (5 mg, 10 mg, 20 mg) in patients with mixed dyslipidemia
ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Data from a new study showed that Abbott 's TRILIPIX(R) (fenofibric acid) delayed-...
Sarah Cannon Research Institute Selects OmniComm Systems' Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
Renowned cancer research center enters into a Technology Transition
agreement with OmniComm to gain more control over the management
of their clinical trials
FT. LAUDERDALE, Fla., Nov. 4 /PRNewswire-FirstCall/ -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM.OB...
U.S. Preventive Medicine Acquires Specialty Disease Management
DALLAS, Oct. 2 /PRNewswire/ -- U.S. Preventive Medicine(R)
(http://www.USPreventiveMedicine.com ) a company organizing and commercializing the
market for proactive preventive health services, announced today the
acquisition of Specialty Disease Management
Services, Inc., a national
The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
WESTBURY, N.Y., Aug. 25 /PRNewswire/ -- "Weight management
business. National health authorities are concerned that more than half of
Americans are over weight, and for many obesity is not merely a matter of
looking unattractive. It is a health hazard. Then why leave it to amateurs
Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
CHAPEL HILL, N.C., Aug. 10 /PRNewswire/ -- More than 33% of
pharmaceutical and biotech companies are able to identify clinical
investigators 50% faster than their industry peers. These companies are
able to significantly reduce clinical trial costs while improving quality
by employing on-going...
Weight Management is Not Enough for Cannabinoid Type 1 (CB1)
Receptor Antagonists to Become a Commercial Success
Huge clinical development program of first-in-class CB1
antagonist rimonabant to show benefits beyond weight reduction and
avoid image as life-style drug
BARCELONA, Spain | March 08, 2007 | The Business Intelligence
firm La Merie S.L. reported today that Sanofi-Aventis’
first-in-class CB1 ...
Oculus Innovative Sciences Microcyn Technology Presented in Poster
at European Wound Management Association Conference
PETALUMA, Calif.--(BUSINESS WIRE)--May 14, 2007 - Oculus Innovative
Sciences, Inc. (NASDAQ:OCLS) today reported that its Microcyn
Technology was the subject of a poster presentation at the European
Association (EWMA) conference that was held in
Glasgow, Scotland this past week.
Vakzine Projekt Management Reports Positive Clinical Trial Results
With Their Therapeutic Prostate Cancer Vaccine VPM4001
HANOVER, Germany--(BUSINESS WIRE)--Jun 1, 2007 - A therapeutic
vaccine developed by the German company VPM to battle prostate
cancer promises new hope for cancer patients. The results of a
successfully completed clinical study will be presented to an
international audience at the Annual Conference ...
Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07
Teleconference to Answer Questions About TA-65, Their Telomerase
Activator With Proven Age Management Benefits
NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation
Sciences, Inc. (T.A. Sciences) recently announced the results of
the Pivotal 2005 Anti-Aging Trial of TA-65, the first human trial
ever to show demonstrated, measurable and positive anti-aging
benefits from a Telomerase Activator. Stati...
Cell Therapeutics, Inc. Management to Discuss Today's Announcement
of Interim Pixantrone Study Results
SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,
July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.
Central European Time members of Cell Therapeutics, Inc.'s (CTI)
management team will host a conference call to discuss today's
announcement of the interim results of its...
Choosing Lab Quality Management Software
Lakeridge Healths large multi-site lab faced challenges with manual document control processes and accreditation management
challenges which were exacerbated by staff shortages and growing test volumes. The lab realized that better document control was essential for accreditation ...
Optimizing Quality Control Data Management
Automation continues to gain importance in modern clinical laboratories in step with increasing test consolidation, rising demands from clinicians for rapid turnaround times, and an ever-mounting shortage of licensed medical technologists. Ultimately, the laboratories that implem...